← Back to Screener
Wave Life Sciences Ltd. Ordinary Shares (WVE)
Price$7.58
Favorite Metrics
Price vs S&P 500 (26W)-10.19%
Price vs S&P 500 (4W)-45.80%
Market Capitalization$1.43B
All Metrics
Book Value / Share (Quarterly)$2.80
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)127.06%
Cash Flow / Share (Quarterly)$-1.00
Price vs S&P 500 (YTD)-60.08%
Net Profit Margin (TTM)-478.33%
EPS (TTM)$-1.21
10-Day Avg Trading Volume3.38M
EPS Excl Extra (TTM)$-1.21
Revenue Growth (5Y)16.30%
EPS (Annual)$-1.21
ROI (Annual)-38.84%
Net Profit Margin (5Y Avg)-1070.11%
Cash / Share (Quarterly)$3.21
Revenue Growth QoQ (YoY)-79.41%
ROA (Last FY)-32.01%
Revenue Growth TTM (YoY)-60.55%
EBITD / Share (TTM)$-1.25
ROE (5Y Avg)-134.48%
Operating Margin (TTM)-504.09%
Cash Flow / Share (Annual)$-1.00
P/B Ratio2.71x
P/B Ratio (Quarterly)5.91x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)19.30x
ROA (TTM)-57.55%
EPS Incl Extra (Annual)$-1.21
Current Ratio (Annual)6.47x
Quick Ratio (Quarterly)6.38x
3-Month Avg Trading Volume6.50M
52-Week Price Return28.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.33
P/S Ratio (Annual)33.39x
Asset Turnover (Annual)0.07x
52-Week High$21.73
Operating Margin (5Y Avg)-1086.85%
EPS Excl Extra (Annual)$-1.21
CapEx CAGR (5Y)-11.73%
26-Week Price Return-1.45%
Quick Ratio (Annual)6.38x
13-Week Price Return-48.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.47x
Enterprise Value$824.598
Revenue / Share Growth (5Y)-13.13%
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)6.05%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-478.33%
Cash / Share (Annual)$3.21
3-Month Return Std Dev111.53%
Net Income / Employee (TTM)$-1
ROE (Last FY)-38.84%
EPS Basic Excl Extra (Annual)$-1.21
Receivables Turnover (TTM)31.67x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.21
Receivables Turnover (Annual)31.67x
ROI (TTM)-82.96%
P/S Ratio (TTM)33.39x
Pretax Margin (5Y Avg)-1066.60%
Revenue / Share (Annual)$0.25
Tangible BV / Share (Annual)$-0.43
Price vs S&P 500 (52W)-6.84%
Year-to-Date Return-55.94%
5-Day Price Return3.17%
EPS Normalized (Annual)$-1.21
ROA (5Y Avg)-50.01%
Net Profit Margin (Annual)-478.33%
Month-to-Date Return3.31%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-1.25
Operating Margin (Annual)-504.09%
ROI (5Y Avg)-134.48%
EPS Basic Excl Extra (TTM)$-1.21
P/B Ratio (Annual)5.91x
Pretax Margin (TTM)-478.33%
Book Value / Share (Annual)$2.80
Price vs S&P 500 (13W)-51.25%
Beta-1.33x
Revenue / Share (TTM)$0.24
ROE (TTM)-82.96%
52-Week Low$5.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
WVEWave Life Sciences Ltd. Ordinary Shares | 33.39x | -60.55% | — | — | $7.58 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
WAVE Life Sciences is a clinical-stage biotech company developing RNA medicines to treat rare and prevalent diseases using its proprietary PRISM platform. The platform combines multiple RNA-targeting modalities—RNA editing, antisense silencing, and RNA interference—with chemistry innovation and genetic insights to optimize drug design and delivery. WAVE's pipeline targets major market opportunities including obesity, Duchenne muscular dystrophy, Huntington's disease, and alpha-1 antitrypsin deficiency.